Harms in Systematic Reviews Paper 1: An introduction to research on harms

被引:37
作者
Qureshi, Riaz [1 ]
Mayo-Wilson, Evan [2 ]
Li, Tianjing [3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[2] Indiana Univ Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, ID USA
[3] Univ Colorado Anschutz Med Campus, Dept Ophthalmol, Aurora, CO USA
关键词
Harms; Systematic Reviews; Meta-analysis; Synthesis; Clinical Trials; RANDOMIZED CONTROLLED-TRIALS; REAL-WORLD; CLINICAL-TRIALS; ADVERSE EVENTS; SAFETY; METAANALYSIS; OUTCOMES; INTERVENTION; CHALLENGES; POOR;
D O I
10.1016/j.jclinepi.2021.10.023
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Most systematic reviews of interventions focus on potential benefits. Common methods and assumptions that are appropriate for assessing benefits can be inappropriate for harms. This paper provides a primer on researching harms, particularly in systematic reviews.Study Design and Setting: Commentary describing challenges with assessing harm.Results: Investigators should be familiar with various terminologies used to describe, classify, and group harms. Published reports of clinical trials include limited information about harms, so systematic reviewers should not depend on these studies and journal articles to reach conclusions about harms. Visualizations might improve communication of multiple dimensions of harms such as severity, relatedness, and timing.Conclusion: The terminology, classification, detection, collection, and reporting of harms create unique challenges that take time, expertise, and resources to navigate in both primary studies and evidence syntheses. Systematic reviewers might reach incorrect conclusions if they focus on evidence about harms found in published reports of randomized trials of a particular health problem. Systematic reviews could be improved through better identification and reporting of harms in primary studies and through better training and uptake of appropriate methods for synthesizing evidence about harms.(c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license ( http:// creativecommons.org/ licenses/ by/ 4.0/ )
引用
收藏
页码:186 / 196
页数:11
相关论文
共 87 条
[1]   Speaking the Same Language: Using Standardized Terminology [J].
Andrews, Jeffrey Campbell ;
Bogliatto, Fabrizio ;
Lawson, HerschelW. ;
Bornstein, Jacob .
JOURNAL OF LOWER GENITAL TRACT DISEASE, 2016, 20 (01) :8-10
[2]  
[Anonymous], 1999, COUNCIL INT ORG MEDI
[3]  
[Anonymous], 2016, NCT01469039 STUD EV
[4]   Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data [J].
Anyanwagu, U. ;
Mamza, J. ;
Gordon, J. ;
Donnelly, R. ;
Idris, I. .
DIABETIC MEDICINE, 2017, 34 (12) :1728-1736
[5]   Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions Implications for Drug Development, Clinical Trials, Pharmacovigilance, Biomarkers, and Monitoring [J].
Aronson, Jeffrey K. .
DRUG SAFETY, 2013, 36 (03) :147-153
[6]   The FDA's Sentinel Initiative-A Comprehensive Approach to Medical Product Surveillance [J].
Ball, R. ;
Robb, M. ;
Anderson, S. A. ;
Dal Pan, G. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (03) :265-268
[7]   An appraisal of meta-analysis guidelines: how do they relate to safety outcomes? [J].
Bennetts, Meg ;
Whalen, Ed ;
Ahadieh, Sima ;
Cappelleri, Joseph C. .
RESEARCH SYNTHESIS METHODS, 2017, 8 (01) :64-78
[8]   Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Mullins, C. Daniel .
VALUE IN HEALTH, 2017, 20 (08) :1003-1008
[9]   Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms [J].
Bougioukas, Konstantinos I. ;
Liakos, Aris ;
Tsapas, Apostolos ;
Ntzani, Evangelia ;
Haidich, Anna-Bettina .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 93 :9-24
[10]  
Chou R, 2008, METHODS GUIDE EFFECT